Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Sep 10, 2010

Premium

Caris Life Sciences this week named Ian Walker vice president of strategic marketing for Europe and Ian Abercrombie vice president of commercial operations for Europe. The new positions "reflect the company's rapid scaling for an aggressive growth strategy in the region," it said.

Previously Abercrombie was European director of oncology at Genzyme and the program director at UK-based start-up Bioenvision. Walker was most recently global programming director of molecular diagnostics for Novartis.


Stefan Gruenwald was appointed this week to the scientific advisory board of Fibrocell Science, a biotech company focusing on the development of autologous cell therapies.

Gruenwald is the co-founder of San Diego-based proteomics firm Orbigen, which merged in 2004 with Biocarta and Chinese biotech reagent company Jingmei.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.